Skip to main content

Table 2 The league table for PFS estimates interventions according to their relative effects in first part network analysis

From: Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

Apatorsen+Taxane (50.9%)a      
− 0.49 (− 1.90,0.93)Vinflunine (79%)     
0.20 (− 1.09,1.49)0.69 (− 0.73,2.11)Vandetanib+Taxane (36.3%)    
0.22 (−0.68,1.13)0.71 (− 0.38,1.80)0.02 (− 0.90,0.94)Taxane (31.7%)   
−0.35 (−1.47,0.77)0.14 (− 1.13,1.41)− 0.55 (− 1.68,0.58)−0.57 (− 1.23,0.09)Ramucirumab+Taxane (75.8%)  
0.31 (− 0.98,1.60)0.80 (− 0.63,2.22)0.11 (− 1.19,1.41)0.09 (− 0.83,1.01)0.66 (− 0.47,1.79)Pazopanib (30.4%) 
0.08 (− 1.24,1.39)0.56 (− 0.88,2.01)− 0.13 (− 1.45,1.20)−0.15 (− 1.10,0.80)0.42 (− 0.73,1.58)− 0.23 (− 1.56,1.09)Icrucumab+Taxane (45.9)
  1. PFS Progression-free Survival
  2. aThe SUCRA probabilities are performed in brackets